Lead Time of Prostate Cancer Detected in Population Based Screening for Prostate Cancer in Japan
Authors:
- 1 October 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 178 (4) , 1258-1264
Abstract
Purpose: We clarified that lead time bias in screen detected prostate cancer is important for evaluating the outcome of any individual screening system. Materials and Methods: Between 1992 and 2001, 195 and 958 prostate cancer cases with clinical T1c/T2N0M0 and T3N0M0 disease were enrolled in the current study as screen detected and outpatient clinic detected prostate cancer, respectively. Log10 prostate specific antigen velocity was calculated using log10 prostate specific antigen at diagnosis and at the most recent screening before cancer detection. Lead time in screen detected cancer was then estimated as the year when log10 prostate specific antigen in screen detected cancer would increase to the levels of log10 prostate specific antigen in outpatient clinic detected prostate cancer. Results: Median log10 prostate specific antigen was 0.87 and 1.08 ng/ml for clinical T1c/T2N0M0 disease, and 1.14 and 1.53 ng/ml for T3N0M0 disease in screen and outpatient clinic detected cancer, respectively. The 25th, 50th and 75th percentiles of log10 prostate specific antigen velocity before cancer detection in the screening population were 0.05, 0.08 and 0.14 for T1c/T2N0M0 disease, and 0.07, 0.13 and 0.21 for T3N0M0 disease, respectively. The 25th, 50th and 75th percentiles of expected lead time in screen detected cancer were 1.9, 3.3 and 5.2 years for T1c/T2N0M0 disease and 1.4, 2.2 and 4.1 years for T3N0M0 disease, respectively. Conclusions: The lead time of screen detected cancer in our screening system is not as long as previously thought. This new methodology for lead time estimation may be useful for evaluating treatment outcomes of screen detected prostate cancer in individual screening systems done in various regions worldwide.Keywords
This publication has 16 references indexed in Scilit:
- Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trialInternational Journal of Cancer, 2001
- Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, AustriaUrology, 2001
- Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000
- DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADAJournal of Urology, 1999
- Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled TrialThe Prostate, 1999
- The European Randomized Study of Screening for Prostate Cancer (ERSPC): An UpdateEuropean Urology, 1999
- Prostate cancer facts and fictionJournal of Surgical Oncology, 1997
- The European randomized study of screening for prostate cancerCancer, 1997
- Natural History of Changes in Prostate Specific Antigen in Early Stage Prostate CancerJournal of Urology, 1994
- Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 MenJournal of Urology, 1994